Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $50.12

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been given an average rating of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $50.1250.

A number of equities research analysts recently weighed in on the stock. Mizuho decreased their price objective on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada dropped their target price on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 7th. Wall Street Zen lowered shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup reaffirmed a “market outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Friday, July 17th.

Insiders Place Their Bets

In other IDEAYA Biosciences news, CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares of the company’s stock, valued at $1,058,904.66. The trade was a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

Institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in shares of IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares in the last quarter. Quantbot Technologies LP bought a new position in IDEAYA Biosciences during the 2nd quarter worth about $43,000. ANTIPODES PARTNERS Ltd grew its holdings in IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after acquiring an additional 380 shares in the last quarter. Global Retirement Partners LLC purchased a new position in IDEAYA Biosciences during the 4th quarter valued at about $61,000. Finally, Nykredit A S purchased a new position in IDEAYA Biosciences during the 2nd quarter valued at about $76,000. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Up 1.4%

IDYA stock opened at $39.67 on Friday. The business’s fifty day simple moving average is $36.14 and its two-hundred day simple moving average is $32.88. IDEAYA Biosciences has a twelve month low of $23.23 and a twelve month high of $40.58. The firm has a market cap of $3.49 billion, a price-to-earnings ratio of -20.45 and a beta of -0.10.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). The company had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm’s revenue for the quarter was up 8800.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.88) earnings per share. Research analysts expect that IDEAYA Biosciences will post -4.38 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.